Based on the findings mentioned above, the stimulating immune effect of an anti-HER2 tyrosine kinase inhibitor, such as lapatinib to potentially increase ADCC against BCAA HER2 protein to induce recruitment and/or expansion of TILs, has led to an emergent field of novel strategies to further exploit immunotherapy in HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.